PDS Biotechnology (FRA:EU6) Total Liabilities: €17.97 Mil (As of Mar. 2026)


FRA:EU6 PDS Biotechnology Corp FRA:EU6
32 GF Score
Price €0.75
! 1 Warning Sign
View Full Analysis

What is PDS Biotechnology Total Liabilities?

PDS Biotechnology FRA:EU6 -2.36% 32 Total Liabilities is €17.97 Mil as of Mar. 2026. GuruFocus rates FRA:EU6 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

PDS Biotechnology's Total Liabilities for the quarter that ended in Mar. 2026 was €17.97 Mil.

PDS Biotechnology's quarterly Total Liabilities declined from Sep. 2025 (€21.52 Mil) to Dec. 2025 (€18.14 Mil) and declined from Dec. 2025 (€18.14 Mil) to Mar. 2026 (€17.97 Mil).

PDS Biotechnology's annual Total Liabilities declined from Dec. 2023 (€30.50 Mil) to Dec. 2024 (€25.17 Mil) and declined from Dec. 2024 (€25.17 Mil) to Dec. 2025 (€18.14 Mil).

PDS Biotechnology Total Liabilities Historical Data

* Premium members only.

The historical data trend for PDS Biotechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PDS Biotechnology Total Liabilities Chart

PDS Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.53 31.16 30.50 25.17 18.14

PDS Biotechnology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.82 21.26 21.52 18.14 17.97
FRA:EU6
32GF Score
PDS Biotechnology Corp FRA:EU6
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PDS Biotechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PDS Biotechnology's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.098+(10.042+0.00099999999999767
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=18.14

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=26.042-7.901
=18.14

PDS Biotechnology's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=8.777+(9.19+-0.00099999999999767
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=17.97

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=21.333-3.367
=17.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €17.97 Mil mean?
PDS Biotechnology (FRA:EU6) has a Total Liabilities of €17.97 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PDS Biotechnology and its competitors.
Is PDS Biotechnology's Total Liabilities too high?
PDS Biotechnology's current Total Liabilities is €17.97 Mil. Overall, PDS Biotechnology has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's Total Liabilities compare to LTRN and AURX?
PDS Biotechnology's Total Liabilities of €17.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PDS Biotechnology and its competitors. PDS Biotechnology's current Total Liabilities is €17.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (FRA:EU6) has a current Total Liabilities of €17.97 Mil. The current Total Liabilities is €17.97 Mil. PDS Biotechnology's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For PDS Biotechnology (FRA:EU6), the current Total Liabilities is €17.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PDS Biotechnology Business Description

Other Exchanges PDSB:USA
Address 303A College Road, East Princeton, NJ, USA, 08540
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
32GF Score

Get the complete analysis for FRA:EU6

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.75
Price